<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112991</url>
  </required_header>
  <id_info>
    <org_study_id>KN035-CN-011</org_study_id>
    <nct_id>NCT05112991</nct_id>
  </id_info>
  <brief_title>Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer</brief_title>
  <official_title>An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3D Medicines (Sichuan) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3D Medicines</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or&#xD;
      with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to&#xD;
      evaluate objective response rate of envafolimab alone or with lenvatinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This study is an open-label, two-arm study, without randomization and blinding</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR of Envafolimab alone or with Lenvatinib</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>The ORR (either confirmed complete response [CR] or partial response [PR]) based on RECIST 1.1 will be determined in participants who have measurable disease at study entry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of response (DoRï¼‰</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall survival (OS) in in subjects with advance endometrial cancer</measure>
    <time_frame>Up to approximately 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Advanced Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Envafolimab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive lenvatinib daily and envafolimab once at the start of each 4-week treatment cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Envafolimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive lenvafolimab once at the start of each 4-week treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envafolimab+Lenvatinib</intervention_name>
    <description>Envafolimab: Envafolimab 400 mg administered subcutaneously on Day 1 of each 28-day cycle. Lenvatinib: the recommended Phase 2 dose (RP2D) orally QD during each 28-day cycle.</description>
    <arm_group_label>Envafolimab + Lenvatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envafolimab</intervention_name>
    <description>Envafolimab: Envafolimab 400 mg administered subcutaneously on Day 1 of each 28-day cycle.</description>
    <arm_group_label>Envafolimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate and sign the informed consent form.&#xD;
&#xD;
          2. Has a histologically confirmed diagnosis of endometrial carcinoma (EC). Has Documented&#xD;
             evidence of advanced, recurrent or metastatic EC and are not candidates for curative&#xD;
             surgery or radiation.&#xD;
&#xD;
          3. Failure or intolerance of standard first-line platinum-based chemotherapy regimen for&#xD;
             EC.&#xD;
&#xD;
             Note: If recurrence occurs during adjuvant/neoadjuvant therapy or within 12 months&#xD;
             after completion, adjuvant/neoadjuvant therapy is considered to be the first-line&#xD;
             treatment for advanced disease. There is no restriction regarding prior hormonal&#xD;
             therapy.&#xD;
&#xD;
          4. Has at least 1 measurable target lesion according to Response Evaluation Criteria In&#xD;
             Solid Tumors (RECIST) 1.1 and confirmed by Blind Independent Imaging Review Committee&#xD;
             (BIRC).&#xD;
&#xD;
          5. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          6. Life expectancy of 12 weeks or more.&#xD;
&#xD;
          7. Sufficient organ and bone marrow function (no hematopoietic growth factor, blood&#xD;
             transfusion or platelet therapy was given within 14 days before the first study drug&#xD;
             treatment).&#xD;
&#xD;
          8. Archival tumor tissue or a newly obtained biopsy must be available prior to the first&#xD;
             dose of study drug for biomarker analysis. Tissue samples need to be from lesions that&#xD;
             have not received local radiotherapy.&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days of the first dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous lab results showed dMMR or MSI-H.&#xD;
&#xD;
          2. Participate in the clinical trials of other investigational drugs within 28 days&#xD;
             before the first medication; or have received anti-tumor treatment within 2 weeks,&#xD;
             including but not limited to chemotherapy and radiotherapy or targeted therapy.&#xD;
&#xD;
          3. The toxicity of previous anti-tumor treatments has not recovered to 0 or 1 level.&#xD;
&#xD;
          4. Recieved major surgery with 28 days before the first medication or has serious&#xD;
             nonhealing wound, ulcer, or bone fracture at screening.&#xD;
&#xD;
          5. Has received prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4&#xD;
             or any other antibody or drug specifically targeting T-cell co-stimulation or&#xD;
             checkpoint pathways.&#xD;
&#xD;
          6. Uncontrolled blood pressure (BP) with or without antihypertensive medications, defined&#xD;
             as BP &gt;150/90 mmHg.&#xD;
&#xD;
          7. Uncontrolled or major Cardio-cerebral vascular disease.&#xD;
&#xD;
          8. Have active, or have had autoimmune diseases or risks that may recur. However,&#xD;
             subjects required only replacement therapy (eg, thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) or&#xD;
             with skin diseases that do not require systemic treatmentare are allowed to be&#xD;
             included.&#xD;
&#xD;
          9. Subjects who need to use corticosteroids (&gt; 10 mg/day prednisone equivalent dose) for&#xD;
             systemic therapy within 14 days before the study drug is administered.&#xD;
&#xD;
         10. Has received a live-virus vaccination within 28 days of planned treatment start or&#xD;
             plan to reveived a live-virus vaccination during the study.&#xD;
&#xD;
         11. Has current or suspected (non-infectious) pneumonitis.&#xD;
&#xD;
         12. Active infection (any infection requiring systemic treatment).&#xD;
&#xD;
         13. Has active Hepatitis B or C.&#xD;
&#xD;
         14. Is positive for Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
         15. Has uncontrolled pericardial effusion, pleural effusion or ascites.&#xD;
&#xD;
         16. Has symptomatic/active brain metastasis or meningeal carcinomatosis; for patients with&#xD;
             brain metastases who have previously received treatment, if the clinical and imaging&#xD;
             evidence does not indicate disease progression within 4 weeks before the first study&#xD;
             drug treatment, and 2 weeks before the first administration There is no need to&#xD;
             receive corticosteroid treatment and can be considered for inclusion.&#xD;
&#xD;
         17. Suffered from other known malignant tumors within 5 years before enrollment (except&#xD;
             for treated skin basal cell carcinoma, skin squamous cell carcinoma and/or carcinoma&#xD;
             in situ after radical resection).&#xD;
&#xD;
         18. Hypersensitivity to either of the study drug or its components.&#xD;
&#xD;
         19. Females who are pregnant or breastfeeding and who refuse to use a highly effective&#xD;
             method of contraception throughout the entire study period, and for 6 months after the&#xD;
             last dose of study drug;&#xD;
&#xD;
         20. According to the judgement of the investigators, there are other factors indicate that&#xD;
             the subject should not be enrolled.&#xD;
&#xD;
         21. Has received prior treatment with any treatment targeting VEGF-directed angiogenesis.&#xD;
&#xD;
         22. Has radiographic evidence of major blood vessel invasion/infiltration.&#xD;
&#xD;
         23. Has a history of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
         24. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other&#xD;
             condition that might affect the absorption of lenvatinib.&#xD;
&#xD;
         25. Has a history of serious bleeding disease within 6 months prior to the first dose of&#xD;
             study drug.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaohua Wu, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>bin She</last_name>
    <phone>15973143911</phone>
    <email>bin.she@3d-medicines.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

